logo
  • 首页
  • 学术期刊
  • 论文检测
  • AIGC检测
  • 热点
  • 更多
    • 数据

Epoprostenol/PembrolizumabLack of efficacy and drug intolerance: case report

被引:0
|
作者:
机构:
来源:
Reactions Weekly | 2024年 / 2028卷 / 1期
关键词:
D O I:
10.1007/s40278-024-67883-3
中图分类号:
学科分类号:
摘要:
引用
收藏
页码:204 / 204
相关论文
共 50 条
  • [41] Catequentinib/pembrolizumabLack of efficacy: case report
    Reactions Weekly, 2021, 1869 (1) : 93 - 93
  • [42] Axitinib/pembrolizumabLack of efficacy: case report
    Reactions Weekly, 2024, 2030 (1) : 81 - 81
  • [43] Catequentinib/pembrolizumabLack of efficacy: case report
    Reactions Weekly, 2022, 1933 (1) : 138 - 138
  • [44] Entinostat/pembrolizumabLack of efficacy: case report
    Reactions Weekly, 2023, 1938 (1) : 595 - 595
  • [45] Dacarbazine/pembrolizumabLack of efficacy : case report
    Reactions Weekly, 2024, 2020 (1) : 170 - 170
  • [46] Nivolumab/pembrolizumabLack of efficacy: case report
    Reactions Weekly, 2022, 1935 (1) : 347 - 347
  • [47] Nivolumab/pembrolizumabLack of efficacy: case report
    Reactions Weekly, 2025, 2040 (1) : 759 - 759
  • [48] PembrolizumabLack of efficacy and hypothyroidism: case report
    Reactions Weekly, 2023, 1950 (1) : 330 - 330
  • [49] Dexamethasone/pembrolizumabLack of efficacy: case report
    Reactions Weekly, 2023, 1970 (1) : 116 - 116
  • [50] Antineoplastics/pembrolizumabLack of efficacy: case report
    Reactions Weekly, 2022, 1919 (1) : 91 - 91
← 12345 →